Therapy Settings Associated with Optimal Outcomes for t:slim X2 with Control-IQ Technology in Real-World Clinical Care
Authors' conclusion
Basal rates, C:I ratios, and Correction Factor settings all impact glycemic outcomes in CIQ users in usual clinical care.
Study context
- Population
- CIQ (t:slim X2 with Control-IQ) users in real-world clinical care; median age 39 years (IQR 19, 59), 55% female, TDI 46.4 U (33–65.2)
- Participants
- 20,764 participants
- Outcome
- Consensus glycemic outcomes (TIR 70-180 mg/dL, time <70 mg/dL, CV) by Correction Factor, C:I ratio and basal rate settings
Methodological detailsreal-world data, deidentified, associative analysis followed by linear regressions
- Real-world data
- Deidentified
- Associative analysis followed by linear regressions
Main finding
As reported in the abstract
Association of therapy settings with glycemic outcomes
- More aggressive Correction Factor, C:I ratio and basal settings strongly associated with higher time in range (TIR) and, to a lesser degree, higher time <70 mg/dL
- Linear regression: more aggressive Correction Factor predicted higher TIR, lower CV, and only negligible impact on time below range
- Higher basal rate and lower C:I ratio predicted increased TIR and increased hypoglycemia
- Most important predictor in all glycemic outcomes: average number of user-given boluses per day
Observational data: associations, not effects.
Original publication
Therapy Settings Associated with Optimal Outcomes for t:slim X2 with Control-IQ Technology in Real-World Clinical Care. Diabetes Technol Ther. Published 25 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →